Did you know? You can suggest edits to improve this peptide information.
Overview
What is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release through activation of the ghrelin receptor (GHS-R1a) and CD36 receptor. Developed in the 1980s as one of the first growth hormone secretagogues, it acts through a PKC/calcium-dependent pathway distinct from GHRH. Beyond GH release, GHRP-6 has demonstrated significant cardioprotective, wound healing, and cytoprotective properties in preclinical and early clinical research. It is notable for its strong appetite-stimulating effects via direct ghrelin receptor activation and its synergistic interaction with GHRH-class peptides.
Key Benefits
Potent GH release, well-characterized pharmacokinetics in human studies, synergistic with GHRH-class peptides, established subcutaneous protocols
Mechanism of Action
Subcutaneous injection provides rapid absorption with distribution half-life of ~7.6 minutes and elimination half-life of ~2.5 hours. Stimulates pulsatile GH release through GHS-R1a activation at pituitary and hypothalamic sites.
Molecular Information
Weight
873.01 Da
Length
6 amino acids
Type
Hexapeptide (met-enkephalin analogue)
Amino Acid Sequence:
His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
* C-terminal amide; D-amino acids at positions 2 (D-Trp) and 5 (D-Phe) for enhanced proteolytic stability and GHS-R1a binding. Molecular formula C₄₆H₅₆N₁₂O₆.
Pharmacokinetics
Research Indications
Growth Hormone Release
Potent GH secretagogue with dose-dependent GH release demonstrated in human clinical studies. Requires endogenous GHRH for maximal effect.
Synergy with GHRH Peptides
Simultaneous stimulation of GHS-R1a and GHRH receptor pathways produces synergistic GH response significantly greater than either peptide alone, as demonstrated in clinical studies combining GHRP and GHRH-class agents
IGF-1 Elevation
Downstream IGF-1 increase from sustained GH release supports anabolic processes and tissue repair
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Inject on empty stomach, 2-3 hours after last meal and 30 minutes before eating. Space injections at least 4 hours apart. Bedtime dose most important for sleep-associated GH pulse.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Quality Indicators
White Lyophilized Powder
Pure GHRP-6 appears as white to off-white lyophilized powder or puck
Clear Reconstituted Solution
Properly reconstituted solution should be crystal clear with no particles
Certificate of Analysis
Should include HPLC purity (>98%), sequence confirmation, and endotoxin testing
Appetite Response Test
Noticeable hunger within 20 minutes of first injection indicates GHS-R1a activation and suggests active peptide. Basic indicator only—HPLC testing required to confirm purity.
No Appetite Response
Absence of hunger after injection may indicate degraded or counterfeit product
Discolored Solution
Yellow or cloudy solution indicates degradation - do not use
What to Expect
- Immediately: Intense hunger within 15-20 minutes of injection, lasting 1-3 hours
- Week 1-2: Improved sleep quality, increased appetite and food intake
- Week 4-6: Changes in body composition (increased lean mass, reduced fat)
- Week 8-12: Peak effects on body composition and recovery
- Side effects: Appetite increase (expected), mild cortisol/prolactin elevation, water retention
- Hunger intensity may diminish after several weeks but does not fully resolve
Side Effects & Safety
- Proven safe in human Phase I dose-escalation clinical trial (IV administration)
- Causes significant appetite increase via ghrelin receptor activation - this is expected, not an adverse effect
- Transiently elevates cortisol and prolactin at doses above 100mcg - usually not clinically significant
- May increase blood glucose and reduce insulin sensitivity with prolonged use
- Avoid use in active cancer - GH and IGF-1 elevation may promote tumor growth
- Inject on empty stomach for optimal GH release - food blunts the response
- Medical supervision recommended, particularly for those with diabetes or insulin resistance
References
Cytoprotective Effects Review (2017)
Comprehensive review establishing GHRPs as cytoprotective agents beyond GH secretion. GHRP-6 demonstrated pharmacological preconditioning across cardiac, renal, pulmonary, and intestinal tissues during ischemia/reperfusion injury via PI-3K/AKT1 pathway activation.
View Study (opens in new tab) →Prevention of Doxorubicin Cardiotoxicity (2024)
Concurrent GHRP-6 administration completely prevented dilated cardiomyopathy in doxorubicin-treated rats, preserving left ventricular systolic function through Bcl-2 upregulation, mitochondrial preservation, and multi-organ protection.
View Study (opens in new tab) →Phase I/II Acute Ischemic Stroke Trial (2024)
Randomized clinical trial of EGF + GHRP-6 combination in acute ischemic stroke. Treated groups showed favorable neurological and functional evolution at 90 and 180 days with higher survival rate and fewer serious adverse events (20-30% vs 56.2% in controls).
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia